

1

DISCLAIMER

This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

straumanngroup

AGENDA

Highlights	Guillaume Daniellot
Financials	Yang Xu
Recent achievements & strategy	Guillaume Daniellot
Outlook 2024	Guillaume Daniellot
Q&A	Guillaume Daniellot, Yang Xu

straumanngroup



THIRD QUARTER WITH STRONG ORGANIC GROWTH

Third quarter revenue in CHF1

586 m

Nine-month: CHF 1.9 billion¹

Digital solutions

Straumann SIRIOS

Global launch enhances the intraoral scanner portfolio

 6 $^{\,_{1}}\%$ of Group total revenue $\,^{2}\,2023$ growth numbers refer to continuing operations

Organic revenue growth^{1,2}

11.2%

Different dynamics in various regions Nine-month: 14.5%

Capacity expansion

China, Brazil

China Campus ramping up, third Neodent factory in Curitiba, Brazil

Regional performance

EMEA

Growth across all businesses

Outlook 2024³ confirmed

Low double-digit organic revenue growth

profitability in the 27-28% range at constant 2023 currency rates⁴

straumanngroup


straumanngroup


5 ¹ Continuous operations ² Excluding FX and M&A effects ³ Barring unforeseen events ⁴ At 2023 full year average exchange rates

GAINING MARKET SHARE IN ALL REGIONS ORGANIC REVENUE GROWTH IN THE THIRD QUARTER **EMEA** Q3 11.4% Q3 2023 NAM Q3 2.0% Q3 2023 5.5% 37,41.2 **GROUP** 03 11.2% Q3 2023 12.1%² **LATAM** Q3 18.9% APAC Q3 2023 19.1% Q3 19.7% Q3 2023


6




















STRAUMANN AXS TO CREATE A UNIQUE CUSTOMER EXPERIENCE AN OPPORTUNITY FOR THE MOST AGILE PLAYERS



15

ONE YEAR EDGE!UP

EMBRACING THE OPPORTUNITIES AND CHALLENGES PRESENTED BY THE DIGITAL AGE



SIGNIFICANT INVESTMENT IN GROWTH WILL CONTINUE

BRAZIL TO BUILD ITS THIRD MANUFACTURING SITE, CHINA CAMPUS RAMPING UP AND HIRING



straumanngroup



OUTLOOK 2024 CONFIRMED

BARRING UNFORESEEN EVENTS

Market environment and assumption

- Uncertain economic environment remains
- Group believes global patient flow should remain stable
- · Outgrowing market vs. prior year

Revenue and profitability

- Organic revenue growth in the low double-digit percentage range
- Profitability in the 27-28% range at constant 2023 currency rates¹

Growth ambition 2030 confirmed

19 ¹ Continuous operations; at 2023 full year average exchange rate


straumanngroup



CALENDAR OF UPCOMING EVENTS

2024	Event	Location
2024	Event	Location
October 30 – 31	ODDO-BHF Europe Roadshow	Paris & Frankfurt
November 6 – 7	ZKB Equity Conference	Zurich
November 15	Barclays 2024 Conversations with the C-Suite	Virtual
November 26 – 27	Stifel Canada Roadshow	Toronto & Montreal
December 3 – 4	Berenberg European Conference	London
December 5	Citi Global Health Care Conference	Miami
December 9 – 12	Barclays USA Roadshow	Boston & New York
February 19, 2025	Full-Year 2024 Results	Webcast, Basel

straumanngroup



ORGANIC NET REVENUE GROWTH

RESTATED FOLLOWING THE SALE OF DRSMILE

	2023					2024			
	1Q	2Q	3Q	4Q		1Q	2Q	3Q	
EMEA	+10.5%	+9.3%	+7.6%	+10.1%		+9.2%	+12.4%	+11.4%	
GROUP	+3.6%	+12.1%	+12.1%	+15.6%	+	+17.5%	+14.8%	+11.2%	
3						straumann grou			